RET/VEGFR3/PDGFRA kinase inhibitor (Guangzhou Liushun Bio-Tec)

N/A

Report date: 2025/01/26 18:45:11

NME

Base Information

Drug NameRET/VEGFR3/PDGFRA kinase inhibitor (Guangzhou Liushun Bio-Tec)

Drug Alias Nameweishuntini (Guangzhou Liushun Bio-Tec)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPlatelet-derived growth factor subunit A inhibitorsTyrosine-protein kinase receptor RET inhibitorsVascular endothelial growth factor receptor 3 antagonists

TargetsVascular endothelial growth factor receptor 3Platelet-derived growth factor subunit ATyrosine-protein kinase receptor RET

Therapy Area/IndicationsSolid tumoursLymphomaNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesGuangzhou Liushun Biological Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Liushun Biological Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursLymphoma

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A